Scinai Immunotherapeutics Finalizes Acquisition of CDMO Arm for Nominal Consideration, Reports Pro Forma Financials
Summary
Scinai Immunotherapeutics Ltd. has filed pro forma financial statements detailing its acquisition of Scinai Biopharma Service Ltd. for nominal consideration, which includes a capital injection and results in a bargain purchase gain, significantly expanding its CDMO capabilities.
Key Events
-
Acquisition of CDMO Business Finalized
Scinai Immunotherapeutics completed the acquisition of Scinai Biopharma Service Ltd. (formerly Recipharm Israel Ltd.), a CDMO (Contract Development and Manufacturing Organization) business, for a nominal consideration of EUR 1.
-
Favorable Acquisition Terms
The transaction included the acquisition of an approximately EUR 13.9 million shareholder loan for nominal consideration and a EUR 2 million capital injection from the seller, Recipharm AB, prior to closing.
-
Bargain Purchase Gain Recognized
The pro forma financial information reflects a bargain purchase gain, attributed to the seller's strategic realignment and regional security conditions, allowing Scinai to acquire the assets at a significant discount.
-
Pro Forma Financial Impact
The unaudited pro forma consolidated financials for 2025 show a combined net loss of approximately $10.96 million, reflecting the integration of the acquired entity which previously had a going concern warning and accumulated deficits.
Analysis
This filing provides the financial details and pro forma impact of Scinai Immunotherapeutics' acquisition of Scinai Biopharma Service Ltd. (formerly Recipharm Israel Ltd.), a CDMO business. The acquisition was completed for a nominal EUR 1, with Scinai also acquiring a significant shareholder loan for nominal consideration and receiving a EUR 2 million capital injection from the seller. This favorable transaction structure led to the recognition of a bargain purchase gain. While the acquired entity had a history of losses and a going concern warning, this strategic move significantly expands Scinai's operational scope into contract development and manufacturing. Investors should note the substantial pro forma combined net loss of approximately $10.96 million for 2025, indicating ongoing financial challenges for the enlarged entity, despite the advantageous acquisition terms.
At the time of this filing, SCNI was trading at $0.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9M. The 52-week trading range was $0.45 to $6.18. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.